By Fineline Cube 
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced the launch of the Phase III MOBILIZE-1 study to evaluate the safety, immunogenicity, and efficacy of V181, a quadrivalent dengue vaccine candidate. The study aims to prevent dengue caused by all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4).
Study Design and Scope
The Phase III MOBILIZE-1 study (V181-005) plans to enroll approximately 12,000 healthy participants aged 2 to 17 years. Participants will be randomly assigned to receive either a single dose of V181 or a placebo. The trial will be conducted at over 30 sites across dengue-endemic regions in the Asia-Pacific, including Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Vietnam.
Initial Recruitment
Initial participant recruitment for the study has already commenced in Singapore, with individuals enrolled regardless of their prior dengue virus exposure.-Fineline Info & Tech